Ocugen Seeks Court Validation of Charter Amendment Dispute

Ocugen ( (OCGN) ) has provided an announcement.

On June 28, 2024, Ocugen’s shareholders voted on a proposal to increase authorized common shares from 295 million to 390 million, and the company subsequently filed a charter amendment on July 10, 2024, after treating the vote as valid based on super-voting Series C preferred stock issued as a dividend to common holders. After a stockholder dispute over whether those preferred shares were eligible to vote under the charter and a related class action filed on October 23, 2025, Ocugen sought to remove uncertainty by filing a Section 205 petition in Delaware’s Court of Chancery on February 12, 2026, asking the court to validate the charter amendment and all common stock issued under it; the court has set a hearing for May 6, 2026, and the plaintiff has agreed that granting the petition would moot her claims.

The dispute centers on whether the Series C preferred stock, created to boost participation among retail investors, met the charter’s requirement that voting shares be entitled to vote generally in director elections, and whether Ocugen’s May 9, 2025 Certificate of Correction properly clarified those rights with retroactive effect. Ocugen maintains it acted in good faith, believes no stockholders were harmed, and warns that failure to validate the amendment could cast doubt on its equity issuances and capital structure, with potential adverse consequences for the company and its shareholders while the litigation and Section 205 proceeding remain unresolved.

The most recent analyst rating on (OCGN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.

Spark’s Take on OCGN Stock

According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses, high leverage, and cash flow strain). Offsetting this, technicals show a constructive uptrend, and recent earnings-call commentary and corporate events point to meaningful pipeline progress and extended liquidity, while valuation remains difficult to justify on earnings given negative profitability.

To see Spark’s full report on OCGN stock, click here.

More about Ocugen

Ocugen, Inc. is a Delaware-incorporated biotechnology company focused on developing biotechnologies and reliant on equity financing and stock-based incentives to fund its business plan and attract, retain, and motivate executives and employees. The company has a large base of retail investors and has historically struggled to achieve quorums at annual shareholder meetings, complicating efforts to secure approval for key corporate actions such as charter amendments.

Average Trading Volume: 5,116,687

Technical Sentiment Signal: Hold

Current Market Cap: $609.9M

For detailed information about OCGN stock, go to TipRanks’ Stock Analysis page.